keyword
MENU ▼
Read by QxMD icon Read
search

interferon beta-1a

keyword
https://www.readbyqxmd.com/read/29209636/neurofilament-light-chain-predicts-disease-activity-in-relapsing-remitting-ms
#1
Kristin N Varhaug, Christian Barro, Kjetil Bjørnevik, Kjell-Morten Myhr, Øivind Torkildsen, Stig Wergeland, Laurence A Bindoff, Jens Kuhle, Christian Vedeler
Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 months thereafter. MRI was performed at baseline and monthly for 9 months and then at months 12 and 24...
January 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29206056/ease-of-use-of-two-autoinjectors-in-patients-with-multiple-sclerosis-treated-with-interferon-beta-1a-subcutaneously-three-times-weekly-results-of-the-randomized-crossover-redefine-study
#2
Sibyl Wray, Brooke Hayward, Fernando Dangond, Barry Singer
BACKGROUND: For interferon beta-1a subcutaneously three times weekly (IFN β-1a SC tiw), administration options include manually injected prefilled syringes; a preassembled, single-use autoinjector; and a reusable autoinjector. This study evaluated patient-perceived ease of use of two injection devices. RESEARCH DESIGN AND METHODS: REDEFINE, a Phase IV, multicenter crossover study, randomized patients with multiple sclerosis and ≥5 weeks' IFN β-1a 44 μg SC tiw use to 4 weeks using a single-use autoinjector, then 4 weeks using a reusable autoinjector, or vice versa...
December 5, 2017: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/29205701/antibody-response-to-seasonal-influenza-vaccination-in-multiple-sclerosis-patients-receiving-immunomodulatory-therapy
#3
Henning K Olberg, Geir Egil Eide, Rebecca J Cox, Åsne Jul-Larsen, Sarah Larteley Lartey, Christian A Vedeler, Kjell-Morten Myhr
BACKGROUND: We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization. OBJECTIVES: To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. METHODS: Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls...
December 4, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29205270/severe-multiple-sclerosis-reactivation-during-prolonged-lymphopenia-after-dimethyl-fumarate-discontinuation
#4
C Zecca, C G Antozzi, V Torri Clerici, M Ferrazzini, R E Mantegazza, S Rossi, C Gobbi
BACKGROUND: Delayed-release dimethyl fumarate (DMF) treatment can be associated with reduced lymphocyte and leucocyte counts, which might persist after DMF discontinuation. CASE PRESENTATION: We report the case of a patient with severe disease reactivation despite prolonged lymphopenia after DMF discontinuation. We describe the frequency and impact of prolonged lymphopenia after DMF discontinuation at two tertiary MS centres. A 36-year-old female patient with multiple sclerosis was switched to DMF after 14 years of treatment with interferon beta-1a...
December 3, 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29178444/alemtuzumab-versus-interferon-beta-1a-for-relapsing-remitting-multiple-sclerosis
#5
REVIEW
Jian Zhang, Shengliang Shi, Yueling Zhang, Jiefeng Luo, Yousheng Xiao, Lian Meng, Xiaobo Yang
BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the treatment of relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity...
November 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29157944/down-regulation-of-tyk2-cblb-and-lmp7-genes-expression-in-relapsing-remitting-multiple-sclerosis-patients-treated-with-interferon-beta
#6
Mehrdokht Mazdeh, Najmeh Moradi, Elnaz Khoshroo, Zahra Shayesteh, Mohammad Taheri, Arezou Sayad, Mir Davood Omrani, Mehrdad Hajilooi, Ghodratollah Roshanaei, Ghasem Solgi
This study aimed to examine the expression of TYK2, CBLB and LMP7 genes at both mRNA and protein levels in relapsing-remitting MS (RRMS) patients in compare with healthy controls. Seventy-eight RRMS patients treated with IFNβ-1a and 79 age- and ethnic-matched healthy subjects were studied. The mRNA expression levels of TYK2, CBLB and LMP7 in PBMCs were quantified by real-time PCR and plasma concentrations of three molecules were measured by ELISA. Results were compared between patients and controls, IFNβ-responders and non-responders...
November 8, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/29153606/pegylated-interferon-beta-in-the-treatment-of-the-theiler-s-murine-encephalomyelitis-virus-mouse-model-of-multiple-sclerosis
#7
Francesca Gilli, Darlene B Royce, Krista D DiSano, Andrew R Pachner
We evaluated the effects of pegylated-interferonβ-1a (pegIFNβ) therapy on intrathecal antibody responses, disability progression, and viral load in the CNS in mice infected with the Theiler's virus (TMEV), an animal model of progressive disability in Multiple Sclerosis (MS). The lack of a direct antiviral activity in the CNS, the absence of any effect upon the intrathecal immune response, and the failure to treat disease progression, indicate that the immunomodulatory effects of pegIFNβ-1a likely occur in the systemic circulation rather than within the CNS...
December 15, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/29141831/long-term-follow-up-of-a-randomized-study-of-combination-interferon-and-glatiramer-acetate-in-multiple-sclerosis-efficacy-and-safety-results-up-to-7-years
#8
Fred D Lublin, Stacey S Cofield, Gary R Cutter, Tarah Gustafson, Stephen Krieger, Ponnada A Narayana, Flavia Nelson, Amber R Salter, Jerry S Wolinsky
BACKGROUND: To report the long-term results of the blinded extension phase of the randomized, controlled study of the combined use of interferon beta-1a (IFN) 30μg IM weekly and glatiramer acetate (GA) 20mg daily compared to each agent alone in relapsing-remitting multiple sclerosis (RRMS). METHODS: 1008 RRMS patients were followed on protocol until the last participant enrolled completed 3 years, allowing some subjects to be followed for up to 7 years. The primary endpoint was reduction in annualized relapse rate...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29141809/treatment-satisfaction-across-injectable-infusion-and-oral-disease-modifying-therapies-for-multiple-sclerosis
#9
Tessa Eagle, Fiona Stuart, Alicia S Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L Cook, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz, Brian C Healy
BACKGROUND: The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies. METHODS: Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29141791/comparing-the-efficacy-of-disease-modifying-therapies-in-multiple-sclerosis
#10
REVIEW
Dimos D Mitsikostas, Douglas S Goodin
Establishing the relative efficacy and safety of the different disease modifying therapies (DMTs) in multiple sclerosis (MS) is critical to the choice of agent that clinicians recommend for individual MS patients. The best evidence for the relative efficacy of the different DMTs comes from head-to-head randomized clinical trials (RCTs). Understanding that outcome-measures with the best established validity are the relapse rate and the actual (not the "confirmed") change in the extended disability status scale (EDSS), we conclude from these head-to-head RCTs that interferon-beta (IFNβ) given subcutaneously multiple times per week (either IFNβ-1b or IFNβ-1a) and glatiramer acetate (GA) are about equivalent in terms of efficacy and that both of these agents, as well as many of the other DMTs, are superior to weekly intramuscular IFNβ-1a...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29139001/the-assessment-for-disinvestment-of-intramuscular-interferon-beta-for-relapsing-remitting-multiple-sclerosis-in-brazil
#11
REVIEW
Livia Lovato Pires de Lemos, Augusto Afonso Guerra Júnior, Marisa Santos, Carlos Magliano, Isabela Diniz, Kathiaja Souza, Ramon Gonçalves Pereira, Juliana Alvares, Brian Godman, Marion Bennie, Ivan Ricardo Zimmermann, Vânia Crisitna Canuto Dos Santos, Clarice Alegre Pretramale, Francisco de Assis Acurcio
In Brazil, inclusion and exclusion of health technologies within the Unified Health System (SUS) is the responsibility of the National Committee for Health Technology Incorporation (CONITEC). A recent Cochrane systematic review demonstrated that intramuscular interferon beta 1a (IFN-β-1a-IM) was inferior to the other beta interferons (IFN-βs) for multiple sclerosis (MS). As a result, CONITEC commissioned an analysis to review possible disinvestment within SUS. The objective of this paper is to describe the disinvestment process for IFN-β-1a-IM in Brazil...
November 14, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29132538/immunometabolic-profiling-of-t-cells-from-patients-with-relapsing-remitting-multiple-sclerosis-reveals-an-impairment-in-glycolysis-and-mitochondrial-respiration
#12
Claudia La Rocca, Fortunata Carbone, Veronica De Rosa, Alessandra Colamatteo, Mario Galgani, Francesco Perna, Roberta Lanzillo, Vincenzo Brescia Morra, Giuseppe Orefice, Ilaria Cerillo, Ciro Florio, Giorgia Teresa Maniscalco, Marco Salvetti, Diego Centonze, Antonio Uccelli, Salvatore Longobardi, Andrea Visconti, Giuseppe Matarese
BACKGROUND: Metabolic reprogramming is shaped to support specific cell functions since cellular metabolism controls the final outcome of immune response. Multiple sclerosis (MS) is an autoimmune disease resulting from loss of immune tolerance against central nervous system (CNS) myelin. Metabolic alterations of T cells occurring during MS are not yet well understood and their studies could have relevance in the comprehension of the pathogenetic events leading to loss of immune tolerance to self and to develop novel therapeutic strategies aimed at limiting MS progression...
December 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/29132404/comparison-of-the-efficacy-and-safety-of-fp-1201-lyo-intravenously-administered-recombinant-human-interferon-beta-1a-and-placebo-in-the-treatment-of-patients-with-moderate-or-severe-acute-respiratory-distress-syndrome-study-protocol-for-a-randomized-controlled
#13
Geoff Bellingan, David Brealey, Jordi Mancebo, Alain Mercat, Nicolò Patroniti, Ville Pettilä, Michael Quintel, Jean-Louis Vincent, Mikael Maksimow, Markku Jalkanen, Ilse Piippo, V Marco Ranieri
BACKGROUND: Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS...
November 13, 2017: Trials
https://www.readbyqxmd.com/read/29081658/understanding-the-positive-benefit-risk-profile-of-alemtuzumab-in-relapsing-multiple-sclerosis-perspectives-from-the-alemtuzumab-clinical-development-program
#14
REVIEW
Eva Havrdova, Jeffrey A Cohen, Dana Horakova, Ivana Kovarova, Eva Meluzinova
The introduction of high-efficacy therapies for relapsing-remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous interferon beta-1a demonstrated significantly reduced annualized relapse rates and improved magnetic resonance imaging outcomes, and were significantly more likely to achieve no evidence of disease activity and reduction in brain volume loss...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29057262/relationship-between-interferon-beta-1a-administration-and-intracranial-vascular-tone-regulation-in-patients-with-relapsing-remitting-multiple-sclerosis-a-pilot-study
#15
Vincenzo Dattola, Lilla Bonanno, Antonino Naro, Antonino Chillura, Anna Lisa Logiudice, Edoardo Sessa, Fausto Famà, Angelo Quartarone, Rocco Salvatore Calabrò, Silvia Marino, Margherita Russo
Interferon beta (IFN-β) therapy is one of the most commonly prescribed immunomodulatory therapies in relapsing-remitting multiple sclerosis (RRMS). A reversible cerebral vasoconstriction syndrome (RCVS), associated with IFN-β use, has been recently described. For this reason, we tested the effect of once a week intramuscular administration of IFN-β-1A on the function of cerebral vessels in a cohort of RRMS patients. Using transcranial Doppler (TCD) ultrasound, we measured the mean blood flow velocity (MFV) in intracranial vessels 10 h after IFN-β administration...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29055471/consistent-efficacy-of-daclizumab-beta-across-patient-demographic-and-disease-activity-subgroups-in-patients-with-relapsing-remitting-multiple-sclerosis
#16
John W Rose, Gavin Giovannoni, Heinz Wiendl, Ralf Gold, Eva Havrdová, Ludwig Kappos, Krzysztof W Selmaj, Jun Zhao, Katherine Riester, L Claire Tsao, Steven J Greenberg
BACKGROUND: Daclizumab beta is a humanized monoclonal antibody specific for the human interleukin-2 receptor alpha chain (CD25). In two pivotal studies in relapsing multiple sclerosis (MS), patients treated with daclizumab beta exhibited lower annualized relapse rates (ARR) when compared with placebo or with intramuscular (IM) interferon beta-1a. OBJECTIVES: To determine if the efficacy of daclizumab beta demonstrated in the phase 2 SELECT study and the phase 3 DECIDE study was consistent in patient subgroups...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29051830/prevalence-of-neutralising-antibodies-to-interferon-beta-and-clinical-response-in-chinese-patients-with-relapsing-multiple-sclerosis
#17
Alexander Y Lau, W K Ip, Cheryl Au, K K Lau, Winnie Wong, K K Yip, Jonas Yeung, S H Li, Patrick Li, Ryan Lee, Deyond Siu, Jill Abrigo, Adrian Wong, Vincent Mok, Eric Chan
BACKGROUND: There are no data on neutralising antibodies to interferon-beta and its clinical implications in Chinese patients with multiple sclerosis (MS). OBJECTIVES: The objectives of this study were to investigate the prevalence of neutralising antibodies among Chinese patients with relapsing MS receiving interferon-beta (1a or 1b) and to study the association between neutralising antibodies and the clinical-radiological response. METHODS: We performed a cross-sectional study on MS patients who received interferon-beta for 9 months or more, and evaluated the clinical response by relapses and magnetic resonance imaging lesions...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29027004/blood-lymphocyte-subsets-identify-optimal-responders-to-ifn-beta-in-ms
#18
Raquel Alenda, Lucienne Costa-Frossard, Roberto Alvarez-Lafuente, Carmen Espejo, Eulalia Rodríguez-Martín, Susana Sainz de la Maza, Noelia Villarrubia, Jordi Río, María I Domínguez-Mozo, Xavier Montalban, José C Álvarez-Cermeño, Luisa M Villar
Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing-remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively...
October 12, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/28984179/efficacy-of-daclizumab-beta-versus-intramuscular-interferon-beta-1a-on-disability-progression-across-patient-demographic-and-disease-activity-subgroups-in-decide
#19
Stanley Cohan, Ludwig Kappos, Gavin Giovannoni, Heinz Wiendl, Krzysztof Selmaj, Eva Kubala Havrdová, John Rose, Steven Greenberg, Glenn Phillips, Wei Ma, Ping Wang, Gabriel Lima, Guido Sabatella
BACKGROUND: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. OBJECTIVE: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE. METHODS: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29 PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined by baseline demographic/disease characteristics...
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28914581/circulating-lymphocyte-levels-and-relationship-with-infection-status-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-daclizumab-beta
#20
Gavin Giovannoni, Heinz Wiendl, Benjamin Turner, Kimberly Umans, Oksana Mokliatchouk, Wanda Castro-Borrero, Steven J Greenberg, Peter McCroskery, Giorgio Giannattasio
BACKGROUND: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing-remitting multiple sclerosis. OBJECTIVE: To analyse total and differential lymphocyte levels and relationship with infection status. METHODS: In DECIDE, blood samples were collected at 12-week intervals from daclizumab beta- ( n = 919) or intramuscular interferon beta-1a-treated ( n = 922) patients. Infections/serious infections were assessed proximate to grade 2/3 lymphopenia or low CD4(+)/CD8(+) T-cell counts...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
80155
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"